nodes	percent_of_prediction	percent_of_DWPC	metapath
Clindamycin—CYP3A4—prostate cancer	0.312	1	CbGaD
Clindamycin—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0914	0.207	CbGbCtD
Clindamycin—CYP3A4—Bicalutamide—prostate cancer	0.048	0.109	CbGbCtD
Clindamycin—CYP3A4—Estramustine—prostate cancer	0.0446	0.101	CbGbCtD
Clindamycin—CYP3A4—Abiraterone—prostate cancer	0.0398	0.09	CbGbCtD
Clindamycin—CYP3A4—Flutamide—prostate cancer	0.0398	0.09	CbGbCtD
Clindamycin—CYP3A4—Cabazitaxel—prostate cancer	0.0294	0.0666	CbGbCtD
Clindamycin—CYP3A4—Estrone—prostate cancer	0.0288	0.0651	CbGbCtD
Clindamycin—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0256	0.058	CbGbCtD
Clindamycin—CYP3A4—Conjugated Estrogens—prostate cancer	0.0188	0.0426	CbGbCtD
Clindamycin—CYP3A4—Mitoxantrone—prostate cancer	0.0171	0.0387	CbGbCtD
Clindamycin—CYP3A4—Estradiol—prostate cancer	0.0165	0.0374	CbGbCtD
Clindamycin—CYP3A4—Prednisone—prostate cancer	0.0142	0.0321	CbGbCtD
Clindamycin—CYP3A4—Etoposide—prostate cancer	0.0108	0.0244	CbGbCtD
Clindamycin—CYP3A4—Docetaxel—prostate cancer	0.00987	0.0223	CbGbCtD
Clindamycin—CYP3A4—Doxorubicin—prostate cancer	0.00736	0.0166	CbGbCtD
Clindamycin—CYP3A4—Farnesoid X Receptor  Pathway—SULT2A1—prostate cancer	0.000255	0.0101	CbGpPWpGaD
Clindamycin—CYP3A4—Fatty Acid Omega Oxidation—CYP2A6—prostate cancer	0.000252	0.00995	CbGpPWpGaD
Clindamycin—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—prostate cancer	0.000244	0.00963	CbGpPWpGaD
Clindamycin—CYP3A4—Tamoxifen metabolism—SULT2A1—prostate cancer	0.000235	0.00931	CbGpPWpGaD
Clindamycin—CYP3A4—Constitutive Androstane Receptor Pathway—CYP3A5—prostate cancer	0.00023	0.00908	CbGpPWpGaD
Clindamycin—CYP3A4—Xenobiotics—CYP2C19—prostate cancer	0.000218	0.00862	CbGpPWpGaD
Clindamycin—CYP3A4—Fatty Acid Omega Oxidation—CYP2E1—prostate cancer	0.000214	0.00846	CbGpPWpGaD
Clindamycin—CYP3A4—Xenobiotics—CYP2A6—prostate cancer	0.000211	0.00832	CbGpPWpGaD
Clindamycin—CYP3A4—Tamoxifen metabolism—CYP2C19—prostate cancer	0.00021	0.00829	CbGpPWpGaD
Clindamycin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP3A43—prostate cancer	0.000208	0.00823	CbGpPWpGaD
Clindamycin—CYP3A4—Oxidation by Cytochrome P450—CYP3A43—prostate cancer	0.000205	0.00812	CbGpPWpGaD
Clindamycin—CYP3A4—Metapathway biotransformation—GSTK1—prostate cancer	0.000203	0.00803	CbGpPWpGaD
Clindamycin—CYP3A4—Metapathway biotransformation—GSTCD—prostate cancer	0.000203	0.00803	CbGpPWpGaD
Clindamycin—CYP3A4—Tamoxifen metabolism—CYP2A6—prostate cancer	0.000202	0.008	CbGpPWpGaD
Clindamycin—CYP3A4—Tryptophan metabolism—CYP7B1—prostate cancer	0.0002	0.00791	CbGpPWpGaD
Clindamycin—CYP3A4—Constitutive Androstane Receptor Pathway—GSTA2—prostate cancer	0.000198	0.00781	CbGpPWpGaD
Clindamycin—CYP3A4—Constitutive Androstane Receptor Pathway—SULT1A1—prostate cancer	0.000195	0.00772	CbGpPWpGaD
Clindamycin—CYP3A4—Estrogen metabolism—NQO1—prostate cancer	0.000193	0.00761	CbGpPWpGaD
Clindamycin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCG5—prostate cancer	0.000186	0.00735	CbGpPWpGaD
Clindamycin—CYP3A4—Estrogen metabolism—CYP1B1—prostate cancer	0.000185	0.0073	CbGpPWpGaD
Clindamycin—CYP3A4—Xenobiotics—CYP2E1—prostate cancer	0.000179	0.00707	CbGpPWpGaD
Clindamycin—CYP3A4—Tamoxifen metabolism—CYP2E1—prostate cancer	0.000172	0.0068	CbGpPWpGaD
Clindamycin—CYP3A4—Aflatoxin activation and detoxification—GGT1—prostate cancer	0.000171	0.00677	CbGpPWpGaD
Clindamycin—CYP3A4—Phase 1 - Functionalization of compounds—CYP3A43—prostate cancer	0.000169	0.00667	CbGpPWpGaD
Clindamycin—CYP3A4—Constitutive Androstane Receptor Pathway—SULT2A1—prostate cancer	0.000168	0.00664	CbGpPWpGaD
Clindamycin—CYP3A4—Tamoxifen metabolism—CYP1B1—prostate cancer	0.000163	0.00645	CbGpPWpGaD
Clindamycin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP7B1—prostate cancer	0.000162	0.0064	CbGpPWpGaD
Clindamycin—CYP3A4—Estrogen metabolism—COMT—prostate cancer	0.000161	0.00638	CbGpPWpGaD
Clindamycin—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—prostate cancer	0.00016	0.00634	CbGpPWpGaD
Clindamycin—CYP3A4—Oxidation by Cytochrome P450—CYP7B1—prostate cancer	0.00016	0.00631	CbGpPWpGaD
Clindamycin—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—prostate cancer	0.000159	0.00628	CbGpPWpGaD
Clindamycin—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—prostate cancer	0.000154	0.00608	CbGpPWpGaD
Clindamycin—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2C19—prostate cancer	0.00015	0.00592	CbGpPWpGaD
Clindamycin—CYP3A4—Estrogen metabolism—GSTM1—prostate cancer	0.000148	0.00583	CbGpPWpGaD
Clindamycin—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2A6—prostate cancer	0.000145	0.00571	CbGpPWpGaD
Clindamycin—CYP3A4—Estrogen metabolism—CYP1A1—prostate cancer	0.00014	0.00553	CbGpPWpGaD
Clindamycin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP3A5—prostate cancer	0.000139	0.00549	CbGpPWpGaD
Clindamycin—CYP3A4—Oxidation by Cytochrome P450—CYP3A5—prostate cancer	0.000137	0.00542	CbGpPWpGaD
Clindamycin—CYP3A4—Tryptophan metabolism—CYP2C18—prostate cancer	0.000135	0.00535	CbGpPWpGaD
Clindamycin—CYP3A4—Irinotecan Pathway—APC—prostate cancer	0.000134	0.0053	CbGpPWpGaD
Clindamycin—CYP3A4—Constitutive Androstane Receptor Pathway—NCOA2—prostate cancer	0.000132	0.00521	CbGpPWpGaD
Clindamycin—CYP3A4—Phase 1 - Functionalization of compounds—CYP7B1—prostate cancer	0.000131	0.00519	CbGpPWpGaD
Clindamycin—CYP3A4—Xenobiotics—CYP1A1—prostate cancer	0.000129	0.00508	CbGpPWpGaD
Clindamycin—CYP3A4—Tamoxifen metabolism—CYP1A1—prostate cancer	0.000124	0.00489	CbGpPWpGaD
Clindamycin—CYP3A4—Cytochrome P450 - arranged by substrate type—TBXAS1—prostate cancer	0.000123	0.00485	CbGpPWpGaD
Clindamycin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—prostate cancer	0.000117	0.00463	CbGpPWpGaD
Clindamycin—CYP3A4—Phase 1 - Functionalization of compounds—CYP3A5—prostate cancer	0.000113	0.00445	CbGpPWpGaD
Clindamycin—CYP3A4—Constitutive Androstane Receptor Pathway—NCOA1—prostate cancer	0.000111	0.00439	CbGpPWpGaD
Clindamycin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C18—prostate cancer	0.000109	0.00432	CbGpPWpGaD
Clindamycin—CYP3A4—Oxidation by Cytochrome P450—CYP2C18—prostate cancer	0.000108	0.00427	CbGpPWpGaD
Clindamycin—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—prostate cancer	0.000106	0.00418	CbGpPWpGaD
Clindamycin—CYP3A4—Biological oxidations—UGT2B15—prostate cancer	0.000101	0.00397	CbGpPWpGaD
Clindamycin—CYP3A4—Biological oxidations—UGT2B17—prostate cancer	0.000101	0.00397	CbGpPWpGaD
Clindamycin—CYP3A4—Phase 1 - Functionalization of compounds—TBXAS1—prostate cancer	9.95e-05	0.00393	CbGpPWpGaD
Clindamycin—CYP3A4—Metapathway biotransformation—UGT2B17—prostate cancer	9.92e-05	0.00392	CbGpPWpGaD
Clindamycin—CYP3A4—Biological oxidations—GSTM3—prostate cancer	9.46e-05	0.00374	CbGpPWpGaD
Clindamycin—CYP3A4—Biological oxidations—SULT2B1—prostate cancer	9.46e-05	0.00374	CbGpPWpGaD
Clindamycin—CYP3A4—Metapathway biotransformation—GSTM3—prostate cancer	9.33e-05	0.00369	CbGpPWpGaD
Clindamycin—CYP3A4—Metapathway biotransformation—SULT2B1—prostate cancer	9.33e-05	0.00369	CbGpPWpGaD
Clindamycin—CYP3A4—Tryptophan metabolism—CYP2E1—prostate cancer	9.19e-05	0.00363	CbGpPWpGaD
Clindamycin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—prostate cancer	9.12e-05	0.00361	CbGpPWpGaD
Clindamycin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C19—prostate cancer	9.06e-05	0.00358	CbGpPWpGaD
Clindamycin—CYP3A4—Biological oxidations—CYP3A43—prostate cancer	8.97e-05	0.00354	CbGpPWpGaD
Clindamycin—CYP3A4—Biological oxidations—NAT1—prostate cancer	8.97e-05	0.00354	CbGpPWpGaD
Clindamycin—CYP3A4—Oxidation by Cytochrome P450—CYP2C19—prostate cancer	8.94e-05	0.00353	CbGpPWpGaD
Clindamycin—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C18—prostate cancer	8.87e-05	0.0035	CbGpPWpGaD
Clindamycin—CYP3A4—Metapathway biotransformation—CYP3A43—prostate cancer	8.84e-05	0.00349	CbGpPWpGaD
Clindamycin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—prostate cancer	8.74e-05	0.00346	CbGpPWpGaD
Clindamycin—CYP3A4—Tryptophan metabolism—CYP1B1—prostate cancer	8.72e-05	0.00344	CbGpPWpGaD
Clindamycin—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—prostate cancer	8.63e-05	0.00341	CbGpPWpGaD
Clindamycin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP17A1—prostate cancer	8.37e-05	0.00331	CbGpPWpGaD
Clindamycin—CYP3A4—Oxidation by Cytochrome P450—CYP17A1—prostate cancer	8.26e-05	0.00327	CbGpPWpGaD
Clindamycin—CYP3A4—Tryptophan metabolism—CYP19A1—prostate cancer	8.2e-05	0.00324	CbGpPWpGaD
Clindamycin—CYP3A4—Cytochrome P450 - arranged by substrate type—NCOA2—prostate cancer	7.98e-05	0.00315	CbGpPWpGaD
Clindamycin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—prostate cancer	7.69e-05	0.00304	CbGpPWpGaD
Clindamycin—CYP3A4—Metapathway biotransformation—EPHX1—prostate cancer	7.52e-05	0.00297	CbGpPWpGaD
Clindamycin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—prostate cancer	7.43e-05	0.00294	CbGpPWpGaD
Clindamycin—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C19—prostate cancer	7.35e-05	0.0029	CbGpPWpGaD
Clindamycin—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—prostate cancer	7.34e-05	0.0029	CbGpPWpGaD
Clindamycin—Dizziness—Conjugated Estrogens—prostate cancer	7.2e-05	0.000327	CcSEcCtD
Clindamycin—Dyspepsia—Mitoxantrone—prostate cancer	7.14e-05	0.000324	CcSEcCtD
Clindamycin—Hypertension—Etoposide—prostate cancer	7.14e-05	0.000324	CcSEcCtD
Clindamycin—Gastrointestinal pain—Estradiol—prostate cancer	7.12e-05	0.000323	CcSEcCtD
Clindamycin—Flushing—Capecitabine—prostate cancer	7.09e-05	0.000322	CcSEcCtD
Clindamycin—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—prostate cancer	7.09e-05	0.0028	CbGpPWpGaD
Clindamycin—Dry skin—Epirubicin—prostate cancer	7.06e-05	0.00032	CcSEcCtD
Clindamycin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—prostate cancer	7.05e-05	0.00278	CbGpPWpGaD
Clindamycin—Abdominal pain upper—Epirubicin—prostate cancer	7.03e-05	0.000319	CcSEcCtD
Clindamycin—Fatigue—Mitoxantrone—prostate cancer	7e-05	0.000318	CcSEcCtD
Clindamycin—Vomiting—Goserelin—prostate cancer	6.98e-05	0.000317	CcSEcCtD
Clindamycin—CYP3A4—Biological oxidations—CYP7B1—prostate cancer	6.97e-05	0.00276	CbGpPWpGaD
Clindamycin—Discomfort—Etoposide—prostate cancer	6.96e-05	0.000316	CcSEcCtD
Clindamycin—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—prostate cancer	6.95e-05	0.00275	CbGpPWpGaD
Clindamycin—Constipation—Mitoxantrone—prostate cancer	6.94e-05	0.000315	CcSEcCtD
Clindamycin—Pain—Mitoxantrone—prostate cancer	6.94e-05	0.000315	CcSEcCtD
Clindamycin—Toxic epidermal necrolysis—Epirubicin—prostate cancer	6.93e-05	0.000315	CcSEcCtD
Clindamycin—Rash—Goserelin—prostate cancer	6.93e-05	0.000314	CcSEcCtD
Clindamycin—Dermatitis—Goserelin—prostate cancer	6.92e-05	0.000314	CcSEcCtD
Clindamycin—Vomiting—Conjugated Estrogens—prostate cancer	6.92e-05	0.000314	CcSEcCtD
Clindamycin—Urticaria—Estradiol—prostate cancer	6.92e-05	0.000314	CcSEcCtD
Clindamycin—Abdominal pain—Estradiol—prostate cancer	6.88e-05	0.000313	CcSEcCtD
Clindamycin—Body temperature increased—Estradiol—prostate cancer	6.88e-05	0.000313	CcSEcCtD
Clindamycin—Headache—Goserelin—prostate cancer	6.88e-05	0.000312	CcSEcCtD
Clindamycin—CYP3A4—Metapathway biotransformation—CYP7B1—prostate cancer	6.88e-05	0.00272	CbGpPWpGaD
Clindamycin—Erythema—Docetaxel—prostate cancer	6.87e-05	0.000312	CcSEcCtD
Clindamycin—Rash—Conjugated Estrogens—prostate cancer	6.86e-05	0.000311	CcSEcCtD
Clindamycin—Dermatitis—Conjugated Estrogens—prostate cancer	6.85e-05	0.000311	CcSEcCtD
Clindamycin—Headache—Conjugated Estrogens—prostate cancer	6.82e-05	0.000309	CcSEcCtD
Clindamycin—CYP3A4—Biological oxidations—SULT1E1—prostate cancer	6.79e-05	0.00268	CbGpPWpGaD
Clindamycin—CYP3A4—Phase 1 - Functionalization of compounds—CYP17A1—prostate cancer	6.79e-05	0.00268	CbGpPWpGaD
Clindamycin—Cardiac arrest—Doxorubicin—prostate cancer	6.77e-05	0.000307	CcSEcCtD
Clindamycin—Anaphylactic shock—Etoposide—prostate cancer	6.75e-05	0.000306	CcSEcCtD
Clindamycin—Dysgeusia—Docetaxel—prostate cancer	6.73e-05	0.000306	CcSEcCtD
Clindamycin—CYP3A4—Cytochrome P450 - arranged by substrate type—NCOA1—prostate cancer	6.72e-05	0.00266	CbGpPWpGaD
Clindamycin—CYP3A4—Metapathway biotransformation—SULT1E1—prostate cancer	6.7e-05	0.00265	CbGpPWpGaD
Clindamycin—Abdominal distension—Epirubicin—prostate cancer	6.7e-05	0.000304	CcSEcCtD
Clindamycin—Erythema—Capecitabine—prostate cancer	6.65e-05	0.000302	CcSEcCtD
Clindamycin—Back pain—Docetaxel—prostate cancer	6.65e-05	0.000302	CcSEcCtD
Clindamycin—Gastrointestinal pain—Mitoxantrone—prostate cancer	6.63e-05	0.000301	CcSEcCtD
Clindamycin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—prostate cancer	6.63e-05	0.00262	CbGpPWpGaD
Clindamycin—Thrombocytopenia—Etoposide—prostate cancer	6.61e-05	0.0003	CcSEcCtD
Clindamycin—Muscle spasms—Docetaxel—prostate cancer	6.61e-05	0.0003	CcSEcCtD
Clindamycin—CYP3A4—Tryptophan metabolism—CYP1A1—prostate cancer	6.61e-05	0.00261	CbGpPWpGaD
Clindamycin—Eosinophilia—Epirubicin—prostate cancer	6.59e-05	0.000299	CcSEcCtD
Clindamycin—Flatulence—Capecitabine—prostate cancer	6.56e-05	0.000298	CcSEcCtD
Clindamycin—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—prostate cancer	6.54e-05	0.00258	CbGpPWpGaD
Clindamycin—Dry skin—Doxorubicin—prostate cancer	6.53e-05	0.000296	CcSEcCtD
Clindamycin—Nausea—Goserelin—prostate cancer	6.52e-05	0.000296	CcSEcCtD
Clindamycin—Dysgeusia—Capecitabine—prostate cancer	6.52e-05	0.000296	CcSEcCtD
Clindamycin—Abdominal pain upper—Doxorubicin—prostate cancer	6.5e-05	0.000295	CcSEcCtD
Clindamycin—CYP3A4—Phase 1 - Functionalization of compounds—NCOA2—prostate cancer	6.47e-05	0.00256	CbGpPWpGaD
Clindamycin—Nausea—Conjugated Estrogens—prostate cancer	6.46e-05	0.000293	CcSEcCtD
Clindamycin—Urticaria—Mitoxantrone—prostate cancer	6.45e-05	0.000293	CcSEcCtD
Clindamycin—Back pain—Capecitabine—prostate cancer	6.44e-05	0.000292	CcSEcCtD
Clindamycin—Hypersensitivity—Estradiol—prostate cancer	6.42e-05	0.000291	CcSEcCtD
Clindamycin—Body temperature increased—Mitoxantrone—prostate cancer	6.41e-05	0.000291	CcSEcCtD
Clindamycin—Abdominal pain—Mitoxantrone—prostate cancer	6.41e-05	0.000291	CcSEcCtD
Clindamycin—Toxic epidermal necrolysis—Doxorubicin—prostate cancer	6.41e-05	0.000291	CcSEcCtD
Clindamycin—Muscle spasms—Capecitabine—prostate cancer	6.4e-05	0.00029	CcSEcCtD
Clindamycin—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—prostate cancer	6.39e-05	0.00253	CbGpPWpGaD
Clindamycin—Anaemia—Docetaxel—prostate cancer	6.35e-05	0.000288	CcSEcCtD
Clindamycin—Flushing—Prednisone—prostate cancer	6.32e-05	0.000287	CcSEcCtD
Clindamycin—Hypotension—Etoposide—prostate cancer	6.31e-05	0.000286	CcSEcCtD
Clindamycin—Asthenia—Estradiol—prostate cancer	6.25e-05	0.000284	CcSEcCtD
Clindamycin—Neutropenia—Epirubicin—prostate cancer	6.22e-05	0.000282	CcSEcCtD
Clindamycin—Dysuria—Epirubicin—prostate cancer	6.22e-05	0.000282	CcSEcCtD
Clindamycin—Abdominal distension—Doxorubicin—prostate cancer	6.2e-05	0.000281	CcSEcCtD
Clindamycin—Upper respiratory tract infection—Epirubicin—prostate cancer	6.18e-05	0.000281	CcSEcCtD
Clindamycin—Pruritus—Estradiol—prostate cancer	6.16e-05	0.00028	CcSEcCtD
Clindamycin—Leukopenia—Docetaxel—prostate cancer	6.15e-05	0.000279	CcSEcCtD
Clindamycin—Anaemia—Capecitabine—prostate cancer	6.15e-05	0.000279	CcSEcCtD
Clindamycin—Eosinophilia—Doxorubicin—prostate cancer	6.09e-05	0.000277	CcSEcCtD
Clindamycin—Photosensitivity reaction—Epirubicin—prostate cancer	6.07e-05	0.000276	CcSEcCtD
Clindamycin—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—prostate cancer	6.03e-05	0.00238	CbGpPWpGaD
Clindamycin—Dyspnoea—Etoposide—prostate cancer	6.02e-05	0.000273	CcSEcCtD
Clindamycin—CYP3A4—Biological oxidations—CYP3A5—prostate cancer	5.98e-05	0.00236	CbGpPWpGaD
Clindamycin—Vertigo—Capecitabine—prostate cancer	5.98e-05	0.000271	CcSEcCtD
Clindamycin—Hypersensitivity—Mitoxantrone—prostate cancer	5.98e-05	0.000271	CcSEcCtD
Clindamycin—Diarrhoea—Estradiol—prostate cancer	5.96e-05	0.00027	CcSEcCtD
Clindamycin—Leukopenia—Capecitabine—prostate cancer	5.96e-05	0.00027	CcSEcCtD
Clindamycin—Hypertension—Docetaxel—prostate cancer	5.93e-05	0.000269	CcSEcCtD
Clindamycin—Erythema—Prednisone—prostate cancer	5.93e-05	0.000269	CcSEcCtD
Clindamycin—CYP3A4—Metapathway biotransformation—CYP3A5—prostate cancer	5.9e-05	0.00233	CbGpPWpGaD
Clindamycin—Stevens-Johnson syndrome—Epirubicin—prostate cancer	5.88e-05	0.000267	CcSEcCtD
Clindamycin—Gastrointestinal disorder—Etoposide—prostate cancer	5.83e-05	0.000265	CcSEcCtD
Clindamycin—Asthenia—Mitoxantrone—prostate cancer	5.82e-05	0.000264	CcSEcCtD
Clindamycin—Fatigue—Etoposide—prostate cancer	5.82e-05	0.000264	CcSEcCtD
Clindamycin—Jaundice—Epirubicin—prostate cancer	5.78e-05	0.000262	CcSEcCtD
Clindamycin—CYP3A4—Biological oxidations—GSTA3—prostate cancer	5.78e-05	0.00228	CbGpPWpGaD
Clindamycin—Pain—Etoposide—prostate cancer	5.77e-05	0.000262	CcSEcCtD
Clindamycin—Constipation—Etoposide—prostate cancer	5.77e-05	0.000262	CcSEcCtD
Clindamycin—Urinary tract infection—Epirubicin—prostate cancer	5.77e-05	0.000262	CcSEcCtD
Clindamycin—Dizziness—Estradiol—prostate cancer	5.76e-05	0.000261	CcSEcCtD
Clindamycin—Dysuria—Doxorubicin—prostate cancer	5.76e-05	0.000261	CcSEcCtD
Clindamycin—Neutropenia—Doxorubicin—prostate cancer	5.76e-05	0.000261	CcSEcCtD
Clindamycin—Hypertension—Capecitabine—prostate cancer	5.74e-05	0.000261	CcSEcCtD
Clindamycin—Upper respiratory tract infection—Doxorubicin—prostate cancer	5.72e-05	0.00026	CcSEcCtD
Clindamycin—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—prostate cancer	5.71e-05	0.00226	CbGpPWpGaD
Clindamycin—CYP3A4—Metapathway biotransformation—GSTA3—prostate cancer	5.7e-05	0.00225	CbGpPWpGaD
Clindamycin—Photosensitivity reaction—Doxorubicin—prostate cancer	5.62e-05	0.000255	CcSEcCtD
Clindamycin—Anaphylactic shock—Docetaxel—prostate cancer	5.61e-05	0.000255	CcSEcCtD
Clindamycin—Discomfort—Capecitabine—prostate cancer	5.6e-05	0.000254	CcSEcCtD
Clindamycin—Epistaxis—Epirubicin—prostate cancer	5.6e-05	0.000254	CcSEcCtD
Clindamycin—Diarrhoea—Mitoxantrone—prostate cancer	5.55e-05	0.000252	CcSEcCtD
Clindamycin—Vomiting—Estradiol—prostate cancer	5.54e-05	0.000251	CcSEcCtD
Clindamycin—Agranulocytosis—Epirubicin—prostate cancer	5.54e-05	0.000251	CcSEcCtD
Clindamycin—Gastrointestinal pain—Etoposide—prostate cancer	5.52e-05	0.000251	CcSEcCtD
Clindamycin—Thrombocytopenia—Docetaxel—prostate cancer	5.49e-05	0.000249	CcSEcCtD
Clindamycin—Rash—Estradiol—prostate cancer	5.49e-05	0.000249	CcSEcCtD
Clindamycin—Dermatitis—Estradiol—prostate cancer	5.49e-05	0.000249	CcSEcCtD
Clindamycin—Anaemia—Prednisone—prostate cancer	5.48e-05	0.000249	CcSEcCtD
Clindamycin—Headache—Estradiol—prostate cancer	5.46e-05	0.000248	CcSEcCtD
Clindamycin—CYP3A4—Phase 1 - Functionalization of compounds—NCOA1—prostate cancer	5.45e-05	0.00215	CbGpPWpGaD
Clindamycin—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	5.44e-05	0.000247	CcSEcCtD
Clindamycin—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—prostate cancer	5.37e-05	0.00212	CbGpPWpGaD
Clindamycin—Urticaria—Etoposide—prostate cancer	5.36e-05	0.000243	CcSEcCtD
Clindamycin—Jaundice—Doxorubicin—prostate cancer	5.35e-05	0.000243	CcSEcCtD
Clindamycin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—prostate cancer	5.34e-05	0.00211	CbGpPWpGaD
Clindamycin—Abdominal pain—Etoposide—prostate cancer	5.34e-05	0.000242	CcSEcCtD
Clindamycin—Body temperature increased—Etoposide—prostate cancer	5.34e-05	0.000242	CcSEcCtD
Clindamycin—Urinary tract infection—Doxorubicin—prostate cancer	5.34e-05	0.000242	CcSEcCtD
Clindamycin—Vertigo—Prednisone—prostate cancer	5.33e-05	0.000242	CcSEcCtD
Clindamycin—Thrombocytopenia—Capecitabine—prostate cancer	5.32e-05	0.000241	CcSEcCtD
Clindamycin—CYP3A4—Biological oxidations—TBXAS1—prostate cancer	5.28e-05	0.00209	CbGpPWpGaD
Clindamycin—CYP3A4—Biological oxidations—GSTA4—prostate cancer	5.28e-05	0.00209	CbGpPWpGaD
Clindamycin—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—prostate cancer	5.27e-05	0.00208	CbGpPWpGaD
Clindamycin—Hypotension—Docetaxel—prostate cancer	5.24e-05	0.000238	CcSEcCtD
Clindamycin—CYP3A4—Metapathway biotransformation—GSTA4—prostate cancer	5.21e-05	0.00206	CbGpPWpGaD
Clindamycin—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—prostate cancer	5.18e-05	0.00205	CbGpPWpGaD
Clindamycin—Epistaxis—Doxorubicin—prostate cancer	5.18e-05	0.000235	CcSEcCtD
Clindamycin—Nausea—Estradiol—prostate cancer	5.17e-05	0.000235	CcSEcCtD
Clindamycin—Vomiting—Mitoxantrone—prostate cancer	5.16e-05	0.000234	CcSEcCtD
Clindamycin—CYP3A4—Biological oxidations—GSTA2—prostate cancer	5.15e-05	0.00203	CbGpPWpGaD
Clindamycin—Agranulocytosis—Doxorubicin—prostate cancer	5.12e-05	0.000233	CcSEcCtD
Clindamycin—Hypertension—Prednisone—prostate cancer	5.12e-05	0.000232	CcSEcCtD
Clindamycin—Rash—Mitoxantrone—prostate cancer	5.12e-05	0.000232	CcSEcCtD
Clindamycin—Dermatitis—Mitoxantrone—prostate cancer	5.11e-05	0.000232	CcSEcCtD
Clindamycin—CYP3A4—Biological oxidations—SULT1A1—prostate cancer	5.09e-05	0.00201	CbGpPWpGaD
Clindamycin—Headache—Mitoxantrone—prostate cancer	5.08e-05	0.000231	CcSEcCtD
Clindamycin—Hypotension—Capecitabine—prostate cancer	5.07e-05	0.00023	CcSEcCtD
Clindamycin—Erythema multiforme—Epirubicin—prostate cancer	5.03e-05	0.000229	CcSEcCtD
Clindamycin—CYP3A4—Metapathway biotransformation—SULT1A1—prostate cancer	5.02e-05	0.00198	CbGpPWpGaD
Clindamycin—Dyspnoea—Docetaxel—prostate cancer	5e-05	0.000227	CcSEcCtD
Clindamycin—Discomfort—Prednisone—prostate cancer	4.99e-05	0.000226	CcSEcCtD
Clindamycin—Hypersensitivity—Etoposide—prostate cancer	4.97e-05	0.000226	CcSEcCtD
Clindamycin—CYP3A4—Biological oxidations—GSTA1—prostate cancer	4.97e-05	0.00196	CbGpPWpGaD
Clindamycin—Flushing—Epirubicin—prostate cancer	4.94e-05	0.000224	CcSEcCtD
Clindamycin—Dyspepsia—Docetaxel—prostate cancer	4.94e-05	0.000224	CcSEcCtD
Clindamycin—CYP3A4—Biological oxidations—GSTO1—prostate cancer	4.91e-05	0.00194	CbGpPWpGaD
Clindamycin—CYP3A4—Biological oxidations—NAT2—prostate cancer	4.91e-05	0.00194	CbGpPWpGaD
Clindamycin—CYP3A4—Metapathway biotransformation—NAT2—prostate cancer	4.84e-05	0.00191	CbGpPWpGaD
Clindamycin—CYP3A4—Metapathway biotransformation—GSTO1—prostate cancer	4.84e-05	0.00191	CbGpPWpGaD
Clindamycin—Gastrointestinal disorder—Docetaxel—prostate cancer	4.84e-05	0.00022	CcSEcCtD
Clindamycin—Asthenia—Etoposide—prostate cancer	4.84e-05	0.00022	CcSEcCtD
Clindamycin—Dyspnoea—Capecitabine—prostate cancer	4.84e-05	0.00022	CcSEcCtD
Clindamycin—Anaphylactic shock—Prednisone—prostate cancer	4.84e-05	0.00022	CcSEcCtD
Clindamycin—Fatigue—Docetaxel—prostate cancer	4.84e-05	0.00022	CcSEcCtD
Clindamycin—Nausea—Mitoxantrone—prostate cancer	4.82e-05	0.000219	CcSEcCtD
Clindamycin—Pain—Docetaxel—prostate cancer	4.8e-05	0.000218	CcSEcCtD
Clindamycin—Constipation—Docetaxel—prostate cancer	4.8e-05	0.000218	CcSEcCtD
Clindamycin—Dyspepsia—Capecitabine—prostate cancer	4.78e-05	0.000217	CcSEcCtD
Clindamycin—Pruritus—Etoposide—prostate cancer	4.78e-05	0.000217	CcSEcCtD
Clindamycin—CYP3A4—Biological oxidations—CYP2C18—prostate cancer	4.71e-05	0.00186	CbGpPWpGaD
Clindamycin—Gastrointestinal disorder—Capecitabine—prostate cancer	4.69e-05	0.000213	CcSEcCtD
Clindamycin—Fatigue—Capecitabine—prostate cancer	4.68e-05	0.000213	CcSEcCtD
Clindamycin—Erythema multiforme—Doxorubicin—prostate cancer	4.66e-05	0.000211	CcSEcCtD
Clindamycin—CYP3A4—Metapathway biotransformation—CYP2C18—prostate cancer	4.64e-05	0.00184	CbGpPWpGaD
Clindamycin—Constipation—Capecitabine—prostate cancer	4.64e-05	0.000211	CcSEcCtD
Clindamycin—Pain—Capecitabine—prostate cancer	4.64e-05	0.000211	CcSEcCtD
Clindamycin—Erythema—Epirubicin—prostate cancer	4.64e-05	0.00021	CcSEcCtD
Clindamycin—Diarrhoea—Etoposide—prostate cancer	4.62e-05	0.00021	CcSEcCtD
Clindamycin—Gastrointestinal pain—Docetaxel—prostate cancer	4.59e-05	0.000208	CcSEcCtD
Clindamycin—Flushing—Doxorubicin—prostate cancer	4.57e-05	0.000208	CcSEcCtD
Clindamycin—Flatulence—Epirubicin—prostate cancer	4.57e-05	0.000207	CcSEcCtD
Clindamycin—Dysgeusia—Epirubicin—prostate cancer	4.54e-05	0.000206	CcSEcCtD
Clindamycin—Back pain—Epirubicin—prostate cancer	4.48e-05	0.000204	CcSEcCtD
Clindamycin—Dizziness—Etoposide—prostate cancer	4.46e-05	0.000203	CcSEcCtD
Clindamycin—Muscle spasms—Epirubicin—prostate cancer	4.46e-05	0.000202	CcSEcCtD
Clindamycin—Gastrointestinal pain—Capecitabine—prostate cancer	4.44e-05	0.000202	CcSEcCtD
Clindamycin—Body temperature increased—Docetaxel—prostate cancer	4.43e-05	0.000201	CcSEcCtD
Clindamycin—Abdominal pain—Docetaxel—prostate cancer	4.43e-05	0.000201	CcSEcCtD
Clindamycin—CYP3A4—Biological oxidations—SULT2A1—prostate cancer	4.38e-05	0.00173	CbGpPWpGaD
Clindamycin—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—prostate cancer	4.33e-05	0.00171	CbGpPWpGaD
Clindamycin—CYP3A4—Metapathway biotransformation—SULT2A1—prostate cancer	4.32e-05	0.00171	CbGpPWpGaD
Clindamycin—Urticaria—Capecitabine—prostate cancer	4.31e-05	0.000196	CcSEcCtD
Clindamycin—Body temperature increased—Capecitabine—prostate cancer	4.29e-05	0.000195	CcSEcCtD
Clindamycin—Abdominal pain—Capecitabine—prostate cancer	4.29e-05	0.000195	CcSEcCtD
Clindamycin—Vomiting—Etoposide—prostate cancer	4.29e-05	0.000195	CcSEcCtD
Clindamycin—Erythema—Doxorubicin—prostate cancer	4.29e-05	0.000195	CcSEcCtD
Clindamycin—Anaemia—Epirubicin—prostate cancer	4.28e-05	0.000195	CcSEcCtD
Clindamycin—Dyspepsia—Prednisone—prostate cancer	4.26e-05	0.000193	CcSEcCtD
Clindamycin—Rash—Etoposide—prostate cancer	4.26e-05	0.000193	CcSEcCtD
Clindamycin—Dermatitis—Etoposide—prostate cancer	4.25e-05	0.000193	CcSEcCtD
Clindamycin—Headache—Etoposide—prostate cancer	4.23e-05	0.000192	CcSEcCtD
Clindamycin—Flatulence—Doxorubicin—prostate cancer	4.23e-05	0.000192	CcSEcCtD
Clindamycin—Dysgeusia—Doxorubicin—prostate cancer	4.2e-05	0.000191	CcSEcCtD
Clindamycin—Fatigue—Prednisone—prostate cancer	4.17e-05	0.000189	CcSEcCtD
Clindamycin—Vertigo—Epirubicin—prostate cancer	4.16e-05	0.000189	CcSEcCtD
Clindamycin—Leukopenia—Epirubicin—prostate cancer	4.15e-05	0.000188	CcSEcCtD
Clindamycin—Back pain—Doxorubicin—prostate cancer	4.15e-05	0.000188	CcSEcCtD
Clindamycin—Constipation—Prednisone—prostate cancer	4.14e-05	0.000188	CcSEcCtD
Clindamycin—Hypersensitivity—Docetaxel—prostate cancer	4.13e-05	0.000188	CcSEcCtD
Clindamycin—Muscle spasms—Doxorubicin—prostate cancer	4.12e-05	0.000187	CcSEcCtD
Clindamycin—CYP3A4—Metapathway biotransformation—GPX3—prostate cancer	4.12e-05	0.00163	CbGpPWpGaD
Clindamycin—CYP3A4—Tryptophan metabolism—MDM2—prostate cancer	4.07e-05	0.00161	CbGpPWpGaD
Clindamycin—Asthenia—Docetaxel—prostate cancer	4.02e-05	0.000183	CcSEcCtD
Clindamycin—Nausea—Etoposide—prostate cancer	4.01e-05	0.000182	CcSEcCtD
Clindamycin—Hypertension—Epirubicin—prostate cancer	4e-05	0.000182	CcSEcCtD
Clindamycin—Hypersensitivity—Capecitabine—prostate cancer	4e-05	0.000182	CcSEcCtD
Clindamycin—Pruritus—Docetaxel—prostate cancer	3.97e-05	0.00018	CcSEcCtD
Clindamycin—Anaemia—Doxorubicin—prostate cancer	3.96e-05	0.00018	CcSEcCtD
Clindamycin—Gastrointestinal pain—Prednisone—prostate cancer	3.96e-05	0.00018	CcSEcCtD
Clindamycin—CYP3A4—Biological oxidations—HPGDS—prostate cancer	3.93e-05	0.00155	CbGpPWpGaD
Clindamycin—CYP3A4—Biological oxidations—CYP2C19—prostate cancer	3.9e-05	0.00154	CbGpPWpGaD
Clindamycin—Discomfort—Epirubicin—prostate cancer	3.9e-05	0.000177	CcSEcCtD
Clindamycin—Asthenia—Capecitabine—prostate cancer	3.9e-05	0.000177	CcSEcCtD
Clindamycin—Vertigo—Doxorubicin—prostate cancer	3.85e-05	0.000175	CcSEcCtD
Clindamycin—CYP3A4—Metapathway biotransformation—CYP2C19—prostate cancer	3.85e-05	0.00152	CbGpPWpGaD
Clindamycin—Urticaria—Prednisone—prostate cancer	3.84e-05	0.000174	CcSEcCtD
Clindamycin—Pruritus—Capecitabine—prostate cancer	3.84e-05	0.000174	CcSEcCtD
Clindamycin—Leukopenia—Doxorubicin—prostate cancer	3.84e-05	0.000174	CcSEcCtD
Clindamycin—Diarrhoea—Docetaxel—prostate cancer	3.84e-05	0.000174	CcSEcCtD
Clindamycin—Abdominal pain—Prednisone—prostate cancer	3.82e-05	0.000174	CcSEcCtD
Clindamycin—Body temperature increased—Prednisone—prostate cancer	3.82e-05	0.000174	CcSEcCtD
Clindamycin—CYP3A4—Biological oxidations—GSTT1—prostate cancer	3.81e-05	0.00151	CbGpPWpGaD
Clindamycin—Anaphylactic shock—Epirubicin—prostate cancer	3.78e-05	0.000172	CcSEcCtD
Clindamycin—CYP3A4—Biological oxidations—CYP2A6—prostate cancer	3.76e-05	0.00149	CbGpPWpGaD
Clindamycin—Diarrhoea—Capecitabine—prostate cancer	3.72e-05	0.000169	CcSEcCtD
Clindamycin—Dizziness—Docetaxel—prostate cancer	3.71e-05	0.000168	CcSEcCtD
Clindamycin—Thrombocytopenia—Epirubicin—prostate cancer	3.7e-05	0.000168	CcSEcCtD
Clindamycin—Hypertension—Doxorubicin—prostate cancer	3.7e-05	0.000168	CcSEcCtD
Clindamycin—CYP3A4—Metapathway biotransformation—AKR1C3—prostate cancer	3.61e-05	0.00143	CbGpPWpGaD
Clindamycin—Discomfort—Doxorubicin—prostate cancer	3.61e-05	0.000164	CcSEcCtD
Clindamycin—CYP3A4—Biological oxidations—CYP17A1—prostate cancer	3.61e-05	0.00142	CbGpPWpGaD
Clindamycin—Dizziness—Capecitabine—prostate cancer	3.59e-05	0.000163	CcSEcCtD
Clindamycin—Vomiting—Docetaxel—prostate cancer	3.57e-05	0.000162	CcSEcCtD
Clindamycin—Hypersensitivity—Prednisone—prostate cancer	3.56e-05	0.000162	CcSEcCtD
Clindamycin—CYP3A4—Metapathway biotransformation—CYP17A1—prostate cancer	3.56e-05	0.00141	CbGpPWpGaD
Clindamycin—Rash—Docetaxel—prostate cancer	3.54e-05	0.000161	CcSEcCtD
Clindamycin—Hypotension—Epirubicin—prostate cancer	3.54e-05	0.00016	CcSEcCtD
Clindamycin—Dermatitis—Docetaxel—prostate cancer	3.53e-05	0.00016	CcSEcCtD
Clindamycin—Headache—Docetaxel—prostate cancer	3.51e-05	0.00016	CcSEcCtD
Clindamycin—Anaphylactic shock—Doxorubicin—prostate cancer	3.5e-05	0.000159	CcSEcCtD
Clindamycin—Asthenia—Prednisone—prostate cancer	3.47e-05	0.000158	CcSEcCtD
Clindamycin—Vomiting—Capecitabine—prostate cancer	3.45e-05	0.000157	CcSEcCtD
Clindamycin—CYP3A4—Biological oxidations—NCOA2—prostate cancer	3.44e-05	0.00136	CbGpPWpGaD
Clindamycin—Thrombocytopenia—Doxorubicin—prostate cancer	3.43e-05	0.000156	CcSEcCtD
Clindamycin—Rash—Capecitabine—prostate cancer	3.42e-05	0.000155	CcSEcCtD
Clindamycin—Pruritus—Prednisone—prostate cancer	3.42e-05	0.000155	CcSEcCtD
Clindamycin—Dermatitis—Capecitabine—prostate cancer	3.42e-05	0.000155	CcSEcCtD
Clindamycin—Headache—Capecitabine—prostate cancer	3.4e-05	0.000154	CcSEcCtD
Clindamycin—Dyspnoea—Epirubicin—prostate cancer	3.37e-05	0.000153	CcSEcCtD
Clindamycin—Nausea—Docetaxel—prostate cancer	3.33e-05	0.000151	CcSEcCtD
Clindamycin—Dyspepsia—Epirubicin—prostate cancer	3.33e-05	0.000151	CcSEcCtD
Clindamycin—Diarrhoea—Prednisone—prostate cancer	3.31e-05	0.00015	CcSEcCtD
Clindamycin—Hypotension—Doxorubicin—prostate cancer	3.27e-05	0.000148	CcSEcCtD
Clindamycin—Gastrointestinal disorder—Epirubicin—prostate cancer	3.27e-05	0.000148	CcSEcCtD
Clindamycin—Fatigue—Epirubicin—prostate cancer	3.26e-05	0.000148	CcSEcCtD
Clindamycin—Constipation—Epirubicin—prostate cancer	3.24e-05	0.000147	CcSEcCtD
Clindamycin—Pain—Epirubicin—prostate cancer	3.24e-05	0.000147	CcSEcCtD
Clindamycin—Nausea—Capecitabine—prostate cancer	3.23e-05	0.000146	CcSEcCtD
Clindamycin—CYP3A4—Biological oxidations—CYP2E1—prostate cancer	3.2e-05	0.00127	CbGpPWpGaD
Clindamycin—Dizziness—Prednisone—prostate cancer	3.2e-05	0.000145	CcSEcCtD
Clindamycin—CYP3A4—Metapathway biotransformation—CYP2E1—prostate cancer	3.16e-05	0.00125	CbGpPWpGaD
Clindamycin—Dyspnoea—Doxorubicin—prostate cancer	3.12e-05	0.000142	CcSEcCtD
Clindamycin—Gastrointestinal pain—Epirubicin—prostate cancer	3.09e-05	0.00014	CcSEcCtD
Clindamycin—Dyspepsia—Doxorubicin—prostate cancer	3.08e-05	0.00014	CcSEcCtD
Clindamycin—Vomiting—Prednisone—prostate cancer	3.08e-05	0.00014	CcSEcCtD
Clindamycin—Rash—Prednisone—prostate cancer	3.05e-05	0.000138	CcSEcCtD
Clindamycin—Dermatitis—Prednisone—prostate cancer	3.05e-05	0.000138	CcSEcCtD
Clindamycin—CYP3A4—Biological oxidations—CYP1B1—prostate cancer	3.03e-05	0.0012	CbGpPWpGaD
Clindamycin—Headache—Prednisone—prostate cancer	3.03e-05	0.000138	CcSEcCtD
Clindamycin—Gastrointestinal disorder—Doxorubicin—prostate cancer	3.02e-05	0.000137	CcSEcCtD
Clindamycin—Fatigue—Doxorubicin—prostate cancer	3.02e-05	0.000137	CcSEcCtD
Clindamycin—Urticaria—Epirubicin—prostate cancer	3.01e-05	0.000136	CcSEcCtD
Clindamycin—Pain—Doxorubicin—prostate cancer	2.99e-05	0.000136	CcSEcCtD
Clindamycin—Constipation—Doxorubicin—prostate cancer	2.99e-05	0.000136	CcSEcCtD
Clindamycin—CYP3A4—Metapathway biotransformation—CYP1B1—prostate cancer	2.99e-05	0.00118	CbGpPWpGaD
Clindamycin—Abdominal pain—Epirubicin—prostate cancer	2.99e-05	0.000136	CcSEcCtD
Clindamycin—Body temperature increased—Epirubicin—prostate cancer	2.99e-05	0.000136	CcSEcCtD
Clindamycin—CYP3A4—Biological oxidations—GGT1—prostate cancer	2.94e-05	0.00116	CbGpPWpGaD
Clindamycin—CYP3A4—Biological oxidations—NCOA1—prostate cancer	2.9e-05	0.00114	CbGpPWpGaD
Clindamycin—Nausea—Prednisone—prostate cancer	2.87e-05	0.00013	CcSEcCtD
Clindamycin—Gastrointestinal pain—Doxorubicin—prostate cancer	2.86e-05	0.00013	CcSEcCtD
Clindamycin—CYP3A4—Biological oxidations—CYP19A1—prostate cancer	2.85e-05	0.00113	CbGpPWpGaD
Clindamycin—CYP3A4—Metapathway biotransformation—CYP19A1—prostate cancer	2.81e-05	0.00111	CbGpPWpGaD
Clindamycin—Hypersensitivity—Epirubicin—prostate cancer	2.79e-05	0.000127	CcSEcCtD
Clindamycin—Urticaria—Doxorubicin—prostate cancer	2.78e-05	0.000126	CcSEcCtD
Clindamycin—Body temperature increased—Doxorubicin—prostate cancer	2.77e-05	0.000126	CcSEcCtD
Clindamycin—Abdominal pain—Doxorubicin—prostate cancer	2.77e-05	0.000126	CcSEcCtD
Clindamycin—CYP3A4—Biological oxidations—RXRA—prostate cancer	2.75e-05	0.00109	CbGpPWpGaD
Clindamycin—Asthenia—Epirubicin—prostate cancer	2.71e-05	0.000123	CcSEcCtD
Clindamycin—Pruritus—Epirubicin—prostate cancer	2.68e-05	0.000122	CcSEcCtD
Clindamycin—CYP3A4—Biological oxidations—COMT—prostate cancer	2.65e-05	0.00105	CbGpPWpGaD
Clindamycin—CYP3A4—Biological oxidations—GSTP1—prostate cancer	2.64e-05	0.00104	CbGpPWpGaD
Clindamycin—CYP3A4—Metapathway biotransformation—COMT—prostate cancer	2.62e-05	0.00103	CbGpPWpGaD
Clindamycin—CYP3A4—Metapathway biotransformation—GSTP1—prostate cancer	2.6e-05	0.00103	CbGpPWpGaD
Clindamycin—Diarrhoea—Epirubicin—prostate cancer	2.59e-05	0.000118	CcSEcCtD
Clindamycin—Hypersensitivity—Doxorubicin—prostate cancer	2.58e-05	0.000117	CcSEcCtD
Clindamycin—Asthenia—Doxorubicin—prostate cancer	2.51e-05	0.000114	CcSEcCtD
Clindamycin—Dizziness—Epirubicin—prostate cancer	2.5e-05	0.000114	CcSEcCtD
Clindamycin—Pruritus—Doxorubicin—prostate cancer	2.48e-05	0.000112	CcSEcCtD
Clindamycin—CYP3A4—Biological oxidations—GSTM1—prostate cancer	2.43e-05	0.000959	CbGpPWpGaD
Clindamycin—Vomiting—Epirubicin—prostate cancer	2.41e-05	0.000109	CcSEcCtD
Clindamycin—Diarrhoea—Doxorubicin—prostate cancer	2.4e-05	0.000109	CcSEcCtD
Clindamycin—CYP3A4—Metapathway biotransformation—GSTM1—prostate cancer	2.39e-05	0.000946	CbGpPWpGaD
Clindamycin—Rash—Epirubicin—prostate cancer	2.39e-05	0.000108	CcSEcCtD
Clindamycin—Dermatitis—Epirubicin—prostate cancer	2.38e-05	0.000108	CcSEcCtD
Clindamycin—Headache—Epirubicin—prostate cancer	2.37e-05	0.000108	CcSEcCtD
Clindamycin—Dizziness—Doxorubicin—prostate cancer	2.31e-05	0.000105	CcSEcCtD
Clindamycin—CYP3A4—Biological oxidations—CYP1A1—prostate cancer	2.3e-05	0.000909	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—HAO1—prostate cancer	2.27e-05	0.000897	CbGpPWpGaD
Clindamycin—CYP3A4—Metapathway biotransformation—CYP1A1—prostate cancer	2.27e-05	0.000896	CbGpPWpGaD
Clindamycin—Nausea—Epirubicin—prostate cancer	2.25e-05	0.000102	CcSEcCtD
Clindamycin—Vomiting—Doxorubicin—prostate cancer	2.23e-05	0.000101	CcSEcCtD
Clindamycin—Rash—Doxorubicin—prostate cancer	2.21e-05	0.0001	CcSEcCtD
Clindamycin—Dermatitis—Doxorubicin—prostate cancer	2.21e-05	0.0001	CcSEcCtD
Clindamycin—Headache—Doxorubicin—prostate cancer	2.19e-05	9.96e-05	CcSEcCtD
Clindamycin—Nausea—Doxorubicin—prostate cancer	2.08e-05	9.44e-05	CcSEcCtD
Clindamycin—CYP3A4—Metabolism—CSAD—prostate cancer	1.85e-05	0.000731	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—GRHL1—prostate cancer	1.85e-05	0.000731	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—PSAT1—prostate cancer	1.85e-05	0.000731	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—CBR1—prostate cancer	1.85e-05	0.000731	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—TST—prostate cancer	1.85e-05	0.000731	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—ADI1—prostate cancer	1.85e-05	0.000731	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—UGT2B15—prostate cancer	1.72e-05	0.00068	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—UGT2B17—prostate cancer	1.72e-05	0.00068	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—CKMT2—prostate cancer	1.72e-05	0.00068	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—GRHPR—prostate cancer	1.72e-05	0.00068	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—NAGLU—prostate cancer	1.62e-05	0.000639	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—MBTPS1—prostate cancer	1.62e-05	0.000639	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—PGAM2—prostate cancer	1.62e-05	0.000639	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—GSTM3—prostate cancer	1.62e-05	0.000639	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—AOX1—prostate cancer	1.62e-05	0.000639	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—SULT2B1—prostate cancer	1.62e-05	0.000639	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—RFK—prostate cancer	1.62e-05	0.000639	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—CYP3A43—prostate cancer	1.53e-05	0.000606	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—AMACR—prostate cancer	1.53e-05	0.000606	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—SRD5A2—prostate cancer	1.53e-05	0.000606	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—NAT1—prostate cancer	1.53e-05	0.000606	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—DEGS1—prostate cancer	1.53e-05	0.000606	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—HSD17B1—prostate cancer	1.46e-05	0.000578	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—HPGD—prostate cancer	1.3e-05	0.000515	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—B4GALT4—prostate cancer	1.3e-05	0.000515	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—TNFRSF21—prostate cancer	1.23e-05	0.000484	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—CYP7B1—prostate cancer	1.19e-05	0.000471	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—MTAP—prostate cancer	1.19e-05	0.000471	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—SULT1E1—prostate cancer	1.16e-05	0.000459	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—SRD5A1—prostate cancer	1.16e-05	0.000459	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—ACSL4—prostate cancer	1.11e-05	0.000438	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—HSD17B3—prostate cancer	1.11e-05	0.000438	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—PHGDH—prostate cancer	1.06e-05	0.00042	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—ARG2—prostate cancer	1.06e-05	0.00042	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—UMPS—prostate cancer	1.06e-05	0.00042	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—LDHB—prostate cancer	1.04e-05	0.000412	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—CYP3A5—prostate cancer	1.02e-05	0.000404	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—TCN2—prostate cancer	9.88e-06	0.00039	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—UCP3—prostate cancer	9.88e-06	0.00039	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—PDHA1—prostate cancer	9.88e-06	0.00039	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—GSTA3—prostate cancer	9.88e-06	0.00039	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—HSD3B1—prostate cancer	9.42e-06	0.000372	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—SLC22A3—prostate cancer	9.42e-06	0.000372	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—GSTA4—prostate cancer	9.04e-06	0.000357	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—TBXAS1—prostate cancer	9.04e-06	0.000357	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—GSTA2—prostate cancer	8.81e-06	0.000348	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—ABCG5—prostate cancer	8.7e-06	0.000344	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—SULT1A1—prostate cancer	8.7e-06	0.000344	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—GSTA1—prostate cancer	8.5e-06	0.000336	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—NAT2—prostate cancer	8.4e-06	0.000332	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—GSTO1—prostate cancer	8.4e-06	0.000332	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—HSD3B2—prostate cancer	8.4e-06	0.000332	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—PLCB2—prostate cancer	8.05e-06	0.000318	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—LRP2—prostate cancer	8.05e-06	0.000318	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—CYP2C18—prostate cancer	8.05e-06	0.000318	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—P4HB—prostate cancer	7.9e-06	0.000312	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—SLC22A1—prostate cancer	7.68e-06	0.000304	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—SULT2A1—prostate cancer	7.49e-06	0.000296	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—MED12—prostate cancer	7.37e-06	0.000291	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—GNG5—prostate cancer	7.31e-06	0.000289	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—NCOA3—prostate cancer	7.04e-06	0.000278	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—HPGDS—prostate cancer	6.72e-06	0.000265	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—CYP2C19—prostate cancer	6.67e-06	0.000264	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—GSTT1—prostate cancer	6.51e-06	0.000257	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—ACHE—prostate cancer	6.51e-06	0.000257	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—CYP2A6—prostate cancer	6.44e-06	0.000254	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—AKR1C3—prostate cancer	6.26e-06	0.000248	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—PRKACB—prostate cancer	6.23e-06	0.000246	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—CYP17A1—prostate cancer	6.17e-06	0.000244	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—NCOA2—prostate cancer	5.88e-06	0.000232	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—SLC5A5—prostate cancer	5.6e-06	0.000221	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—CYP2E1—prostate cancer	5.47e-06	0.000216	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—NQO1—prostate cancer	5.41e-06	0.000214	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—TH—prostate cancer	5.33e-06	0.000211	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—CYP1B1—prostate cancer	5.19e-06	0.000205	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—GGT1—prostate cancer	5.03e-06	0.000199	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—NCOA1—prostate cancer	4.95e-06	0.000196	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—CYP19A1—prostate cancer	4.88e-06	0.000193	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—RXRA—prostate cancer	4.71e-06	0.000186	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—COMT—prostate cancer	4.54e-06	0.000179	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—GSTP1—prostate cancer	4.51e-06	0.000178	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—ITPR1—prostate cancer	4.44e-06	0.000176	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—TYMS—prostate cancer	4.2e-06	0.000166	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—GSTM1—prostate cancer	4.15e-06	0.000164	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—LPL—prostate cancer	4.07e-06	0.000161	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—CYP1A1—prostate cancer	3.93e-06	0.000155	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—ERCC2—prostate cancer	3.9e-06	0.000154	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—MTHFR—prostate cancer	3.67e-06	0.000145	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—PPARA—prostate cancer	3.6e-06	0.000142	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—CAV1—prostate cancer	3.38e-06	0.000134	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—PIK3CG—prostate cancer	3.08e-06	0.000122	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—INS—prostate cancer	2.92e-06	0.000115	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—CREBBP—prostate cancer	2.86e-06	0.000113	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—PIK3CD—prostate cancer	2.71e-06	0.000107	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—NOS3—prostate cancer	2.56e-06	0.000101	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—PIK3CB—prostate cancer	2.36e-06	9.33e-05	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—PTGS2—prostate cancer	2.34e-06	9.24e-05	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—PTEN—prostate cancer	2.04e-06	8.06e-05	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—EP300—prostate cancer	1.95e-06	7.69e-05	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—PIK3CA—prostate cancer	1.44e-06	5.69e-05	CbGpPWpGaD
Clindamycin—CYP3A4—Metabolism—AKT1—prostate cancer	1.18e-06	4.65e-05	CbGpPWpGaD
